Articles
Solving Challenges and Pain Points for Complex Global Clinical Trials
Clinical trials are evolving away from trials based solely at investigator sites, moving on to the patient’s home, requiring direct-to-patient services in order for patients to participate.
Homecare networks are now responsible for not only patient treatment, but also for...
Articles
The Importance of the Human Touch in Improving Clinical Trial Patient-Centricity
Patient-centricity has become an important focus for drug developers and an essential element of clinical studies aimed at showing that a new therapy addresses real patient needs. How companies define patient-centric trials sometimes differ.
But to patients themselves, it typically...
Clinical Trials
Cmed to Demonstrate the Capture, Visualization and RTA of Clinical Data using encapsia® at Mobile in Clinical Trials and DPharm 2017
Cmed has announced it will present its encapsia® clinical data suite at Mobile in Clinical Trials and DPharm: Disruptive Innovations to Advance Clinical Trials 2017. Attendees at both conferences will have the opportunity to learn about...
Clinical Trials
Initiation of Cytisine Clinical Development Program Announced By Achieve
Achieve Life Sciences, Inc. a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced initiation of the Cytisine Clinical Development Program. Cytisine is an established smoking cessation treatment...
Clinical Trials
BioSight Completed Patient Enrollment and Treatment in its Extended Acute Leukemia Phase I/II Clinical Trial
BioSight, Ltd, a pharmaceutical development company, focused on the development of targeted oncology therapeutics with reduced toxicity, announced completion of last patient treatment in its extended Phase I/II clinical study of BST-236 (Astarabine) in acute leukemia patients. ...
Clinical Trials
Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia Completed By Biohaven
Biohaven Pharmaceutical Holding Company Ltd. announced today that it has commenced dosing of all 141 randomized patients with spinocerebellar ataxia (SCA) in its Phase 2/3 trial of trigriluzole (previously known as BHV-4157). Â As a result, Biohaven...
Clinical Trials
Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin LymphomaÂ
Kite Pharma, Inc , a leading cell therapy company announced that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL) are now being treated in its Phase 2 ZUMA-5 trial with its lead investigational candidate, axicabtagene ciloleucel (axi-cel). ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
